Arbutus Biopharma Corporation
Biotechnology, 701 Veterans Circle, Warminster, Pennsylvania, 18974, United States, 51-200 Employees
Who is ARBUTUS BIOPHARMA CORPORATION
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with dist...
Read More
-
Headquarters: 701 Veterans Circle, Warminster, Pennsylvania, 18974, United States
-
Date Founded: 2005
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
-
CEO:
William Collier
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ARBUTUS BIOPHARMA CORPORATION
Arbutus Biopharma Corporation Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Arbutus Biopharma Corporation
Answer: Arbutus Biopharma Corporation's headquarters are located at 701 Veterans Circle, Warminster, Pennsylvania, 18974, United States
Answer: Arbutus Biopharma Corporation's official website is https://arbutusbio.com
Answer: Arbutus Biopharma Corporation's revenue is $50 Million to $100 Million
Answer: Arbutus Biopharma Corporation's SIC: 2834
Answer: Arbutus Biopharma Corporation's NAICS: 325412
Answer: Arbutus Biopharma Corporation has 51-200 employees
Answer: Arbutus Biopharma Corporation is in Biotechnology
Answer: Arbutus Biopharma Corporation contact info: Phone number: Website: https://arbutusbio.com
Answer: Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
CEO at Arbutus Biopharma Corporation
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month